3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
12
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
5
Breast Diseases
4
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Neoplasms
3
Lung Diseases
3
Bronchial Neoplasms
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Melanoma
2
Kidney Neoplasms
2
Endocrine Gland Neoplasms
2
Digestive System Neoplasms
2
Respiratory Tract Diseases
1
Ovarian Neoplasms
1
Ovarian Diseases
1
Neoplasms by Site
1
Mammary Neoplasms, Animal
1
Hodgkin Disease
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Bronchogenic
1
Advanced Breast Cancer
1
Interventions
Carboplatin
6
Pemetrexed
5
pembrolizumab
3
selpercatinib
2
pralsetinib
2
osimertinib
2
durvalumab
2
camrelizumab
2
Cisplatin
2
taletrectinib
1
repotrectinib
1
motexafin gadolinium
1
exemestane
1
entinostat
1
ceralasertib
1
belinostat
1
belagenpumatucel L
1
alectinib
1
TNFSF10 protein, human
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oncolytic Virotherapy
1
Injections
1
Gemcitabine
1
Fluorouracil
1
Erlotinib Hydrochloride
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Bronchogenic
×
entinostat
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled